Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 15/20 | 1.00 |
| ▸ | DRD2 | P14416 | 9/20 | 1.00 |
| ▸ | DRD5 | P21918 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | ADCY5 | O95622 | 2/20 | 1.00 |
| ▸ | ADCY6 | O43306 | 1/20 | 1.00 |
| ▸ | ADCY3 | O60266 | 1/20 | 1.00 |
| ▸ | ADCY9 | O60503 | 1/20 | 1.00 |
| ▸ | ADCY8 | P40145 | 1/20 | 1.00 |
| ▸ | ADCY7 | P51828 | 1/20 | 1.00 |
| ▸ | ADCY2 | Q08462 | 1/20 | 1.00 |
| ▸ | ADCY1 | Q08828 | 1/20 | 1.00 |
| ▸ | ADCY4 | Q8NFM4 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Skf-38393 SCHEMBL29389401 | 1.00 | DRD1 (1.00) | DRD1DRD2DRD5KDM4EHPGD | |
| (R)-Skf-38393 SCHEMBL7941051 | 1.00 | DRD1 (1.00) | DRD1DRD2DRD5KDM4EHPGD | |
| Skf-38393 SCHEMBL29387587 | 0.98 | DRD1 (1.00) | DRD1DRD2DRD5KDM4EHPGD | |
| (R)-Skf-38393 SCHEMBL7201396 | 0.98 | DRD1 (1.00) | DRD1DRD2DRD5KDM4EHPGD | |
| Skf-38393 SCHEMBL1874365 | 0.98 | DRD1 (1.00) | DRD1DRD2DRD5KDM4EHPGD | |
| (R)-Skf-38393 SCHEMBL7201583 | 0.98 | DRD1 (1.00) | DRD1DRD2DRD5KDM4EHPGD | |
| (R)-Skf-38393 SCHEMBL29634867 | 0.98 | DRD1 (1.00) | DRD1DRD2DRD5KDM4EHPGD | |
| Skf-38393 SCHEMBL3425787 | 0.98 | DRD1 (1.00) | DRD1DRD2DRD5KDM4EHPGD | |
| Skf-38393 SCHEMBL30287850 | 0.97 | DRD1 (0.97) | DRD1DRD2DRD5KDM4EHPGD | |
| Skf-38393 SCHEMBL10604872 | 0.93 | DRD1 (0.87) | DRD1DRD2DRD5KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4717276-A2 | OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | University of Canberra (AU) | 2026-04-01 | — | — | EP | claimed |
| EP-3442516-B1 | OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | UNIV CANBERRA (AU) | 2025-11-12 | — | — | EP | claimed |
| CN-112770734-B | Inhibition method | 堪培拉大学 | 2024-08-20 | — | — | CN | claimed |
| US-11890266-B2 | Ophthalmic compositions including levodopa, an antioxidant and an aqueous carrier | UNIVERSITY OF CANBERRA (AU) | 2024-02-06 | — | — | US | claimed |
| EP-4011367-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2022-06-15 | — | — | EP | claimed |
| US-20220047529-A1 | METHODS OF INHIBITION | UNIVERSITY OF CANBERRA (AU) | 2022-02-17 | — | — | US | claimed |
| CN-112770734-A | Suppression method | 堪培拉大学 | 2021-05-07 | — | — | CN | claimed |
| US-20210077443-A1 | OPHTHALMIC COMPOSITIONS INCLUDING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | UNIVERSITY OF CANBERRA (AU) | 2021-03-18 | — | — | US | claimed |
| US-10874629-B2 | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | UNIVERSITY OF CANBERRA (AU) | 2020-12-29 | — | — | US | claimed |
| US-20190151270-A1 | OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | UNIVERSITY OF CANBERRA (AU) | 2019-05-23 | — | — | US | claimed |
| EP-3442516-A1 | OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | University of Canberra (AU) | 2019-02-20 | — | — | EP | claimed |
| WO-2017177262-A1 | OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | UNIVERSITY OF CANBERRA (AU) | 2017-10-19 | — | — | WO | claimed |
| US-6706704-B2 | SYNGERGISTIC MIXTURE OF OPIOD AND DOPAMINE RECEPTOR ANTAGONIST | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2004-03-16 | — | — | US | claimed |
| US-20030092701-A1 | Method of inducing opioid analgesia and anesthesia without respiratory suppression | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-05-15 | — | — | US | claimed |
| EP-0167204-B1 | METHOD FOR IMPROVING THE ABSORPTION AND EFFECTIVENESS OF A CATECHOLAMINE COMPOUND | SIMES S.p.A. Società Italiana Medicinali e Sintetici (IT) | 1989-09-27 | — | — | EP | claimed |
| EP-0244088-A2 | 1-Phenyl-3-benzazepine compounds and medicaments containing these compounds for treating gastrointestinal motility disorders | SMITHKLINE BEECHAM CORPORATION (US) | 1987-11-04 | — | — | EP | claimed |
| EP-4717276-A2 | OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | University of Canberra (AU) | 2026-04-01 | — | — | EP | disclosed |
| EP-3442516-B1 | OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | UNIV CANBERRA (AU) | 2025-11-12 | — | — | EP | disclosed |
| US-4052506-A | BENZAZEPINES | SMITHKLINE CORPORATION (US) | 1977-10-04 | — | — | US | disclosed |
| US-4011319-A | STIMULATING DOPAMINE RECEPTORS, RENAL VASODILATORS, DIURETICS | SMITHKLINE CORPORATION (US) | 1977-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220047529-A1 | METHODS OF INHIBITION | SLC6A3, DBH, SNCA | DRD1 4/4885DRD2 5/4885DRD5 21/4885 |
| US-11890266-B2 | Ophthalmic compositions including levodopa, an antioxidant and an aqueous carrier | TTPA, TST, TXN2 | DRD1 1876/4885DRD2 2171/4885DRD5 3558/4885 |
| US-10874629-B2 | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | COMT, LRRK2, PARK7 | DRD1 341/4885DRD2 225/4885DRD5 1258/4885 |
| US-20190151270-A1 | OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | COMT, LRRK2, PARK7 | DRD1 341/4885DRD2 225/4885DRD5 1258/4885 |
| US-20210077443-A1 | OPHTHALMIC COMPOSITIONS INCLUDING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | TTPA, TST, TXN2 | DRD1 1876/4885DRD2 2171/4885DRD5 3558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.